

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2015/116880 A1

(43) International Publication Date
6 August 2015 (06.08.2015)

(51) International Patent Classification:

A61K 45/06 (2006.01) A61P 3/10 (2006.01)
A61K 31/401 (2006.01) A61P 1/16 (2006.01)
A61K 31/4164 (2006.01) A61K 31/7042 (2006.01)
A61K 31/7034 (2006.01) A61K 31/4439 (2006.01)
A61P 13/12 (2006.01)

(21) International Application Number:

PCT/US2015/013644

(22) International Filing Date:

30 January 2015 (30.01.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/934,003 31 January 2014 (31.01.2014) US
61/948,882 6 March 2014 (06.03.2014) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor: USISKIN, Keith S.; 3 Ogden Road, Mendham,
New Jersey 07945 (US).

(74) Agents: PLANTZ, Bernard F. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS FOR THE TREATMENT AND PREVENTION OF RENAL DISORDERS AND FATTY LIVER DIS-
ORDERS

(57) Abstract: The present invention is directed to methods for treating, delaying, slowing the progression of and / or preventing disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consist-
ing or consisting essentially of (a) canagliflozin and (b) one or more ACE inhibitors or one or more ARBs or one or more PPAR-
gamma agonists; and to methods for treating, delaying, slowing the progression of and / or preventing fatty liver disorders (for ex-
ample, NASH or NAFLD), comprising administering to a subject in need thereof a therapeutically effective amount of canagliflozin.

WO 2015/116880 A1